source: International Journal of Cardiology Cardiovascular Risk and Prevention
Abstract
Among hypertensive patients with CKD, SGLT2 inhibitors significantly reduce renal disease progression and cardiovascular events while maintaining favorable safety. These findings support their integration into standard therapy for this high-risk population.
Concepts :
Blood Pressure and Hypertension Studies
Diabetes Treatment and Management
Chronic Kidney Disease and Diabetes
article
cite 1
Year 2026
source International Journal of Cardiology Cardiovascular Risk and Prevention